Rob van Hegelsom

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The cell surface ecto-enzyme CD38 is a promising target antigen for the treatment of hematological malignancies, as illustrated by the recent approval of daratumumab for the treatment of multiple myeloma. Our aim was to evaluate the potential of CD38-specific nanobodies as novel diagnostics for hematological malignancies. We successfully identified 22(More)
  • 1